Biocon Limited has entered into a global patent settlement and licence agreement with Genentech, a subsidiary of Roche, resolving pending disputes over Pebrilzo, its biosimilar to Perjeta (pertuzumab), a biologic medicine used to treat HER2-positive breast cancer. The agreement establishes launch timelines for the drug
Bharat Serums and Vaccines (BSV), a leading biopharmaceutical company in India reaffirms its commitment to spur innovation and scientific research through its world class R&D centre at Airoli, Maharashtra. The state-of-art centre was inaugurated by Shri Rajesh Tope, Maharashtra's Health Minister yesterday. Also present at
First and only minimally invasive, transcatheter treatment specifically approved for premature babies with patent ductus, a life-threatening opening in their heart (a common congenital defect) One-fifth of 240,000 children born in India with congenital heart defects need early intervention to survive the first year
Join 2M+ industry professionals with MedgateToday - curated insights, delivered daily.
